Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ALS TDI, California Stem Cell ally in ALS treatment

Executive Summary

The ALS Therapy Development Institute (ALS TDI) and start-up California Stem Cell (human embryonic stem cell therapies) have allied in a long-term R&D collaboration to advance stem cell therapies for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative condition also known as Lou Gehrig's disease.
Deal Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies